Fatty Acid and Lipid Metabolism Antibody…

The University of Nebraska Medical Center, a state agency operating under the Board of Regents of the University of Nebraska in Nebraska, awarded a purchase order to Cell Signaling Technology Inc., headquartered in Boston, Massachusetts, for the procurement of research-grade antibodies. The contract, issued on September 3, 2026, with a performance period ending September 7, 2026, covers one unit of Fatty Acid and Lipid Metabolism Antibody (material number 99729T) valued at $793. Delivery is directed to UNMC General Supply in Omaha, Nebraska, under Free on Board destination freight prepaid shipping terms.

The purchase order is classified as a standard procurement vehicle subject to Net 30 payment terms, with payment to be rendered via Nebraska State Treasury warrant. The vendor is required to acknowledge acceptance of the order within ten days of issuance. The transaction is governed by the Standard Terms of Purchase established by the University of Nebraska unless superseded by a separate agreement executed between Cell Signaling Technology Inc. and the Board of Regents. This acquisition supports research and medical laboratory operations at the Medical Center.